Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Update

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 68,300 shares, a decline of 55.3% from the November 15th total of 152,900 shares. Based on an average daily volume of 471,000 shares, the short-interest ratio is currently 0.1 days. Approximately 1.5% of the shares of the company are short sold.

Entero Therapeutics Stock Down 6.8 %

ENTO stock traded down $0.04 during midday trading on Friday, hitting $0.58. The stock had a trading volume of 72,549 shares, compared to its average volume of 364,733. The stock has a 50-day simple moving average of $0.57 and a 200 day simple moving average of $0.86. Entero Therapeutics has a 52 week low of $0.19 and a 52 week high of $14.51.

Entero Therapeutics (NASDAQ:ENTO) last issued its quarterly earnings data on Monday, October 21st. The company reported ($3.37) earnings per share (EPS) for the quarter. Analysts predict that Entero Therapeutics will post -1.13 earnings per share for the current year.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.